List view / Grid view
25 April 2017 | By Niamh Marriott, Junior Editor
Pfizer's results show patients diagnosed with hospital-acquired pneumonia (HAP) treated with Zavicefta or Meropenem experienced comparable rates of cure...
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
23 March 2017 | By Niamh Marriott, Junior Editor
According to a new report, the global injectable drug delivery market is projected to reach US$624.50 Billion by 2021 from US$362.38 billion in 2016...
20 February 2017 | By Niamh Marriott, Digital Editor
Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
9 December 2016 | By Niamh Louise Marriott, Digital Editor
Pharma Giant Pfizer has been fined a record £84.2 million after it broke competition law by charging excessive and unfair prices to the UK...
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
19 October 2016 | By Viavi Solutions Inc.
In this webinar, experts from Viavi, Pfizer & Université Laval discussed how MicroNIR is used to optimise fluid bed drying and to reduce waste at tablet compression...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund...
24 August 2016 | By Pfizer
The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL...
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
8 August 2016 | By Pfizer
Treatement over varying periods of up to 5.5 years, showed that early stage treatment with Vyndaqel resulted in minimal neurological disease progression, and in preservation of body weight, which often declines as the disease progresses...
